The average price reduction of drugs newly admitted to medical insurance, negotiation and bidding, such as Azovudine and other COVID-19 therapeutic drugs, reached 60.1%, and it is estimated that the burden of patients will be reduced by more than 90 billion yuan in the next two years... The latest version of the National Medical Insurance Drug Catalog was announced in Beijing on the 18th. What are the highlights of the new medical insurance drug catalogue worth paying attention to? What will be the impact of medication on the people? The National Health Insurance Bureau held a press conference on the same day to respond. 111 drugs were included in many fields such as COVID-19, rare disease treatment, etc. At present, the total number of drugs in the adjusted national medical insurance drug list reached 2967, and the new drugs covered 2 COVID-19 drugs for treatment, 7 drugs for rare diseases, 22 drugs for children, etc. After Azovudine Tablets and Qingfei Paidu Granules were included in the national medical insurance drug list through this negotiation, there were more than 600 drugs in the national medical insurance drug list for the treatment of COVID-19 symptoms such as fever and cough. "In 2022, the list will be adjusted to support domestic innovative drugs, COVID-19 therapeutic drugs, children's drugs and other drugs in key areas." Huang Xinyu, Deputy Director of the Medical Service Management Department of the National Health Insurance Bureau, said that drugs for major diseases such as cancer and rare diseases, and drugs for chronic diseases such as diabetes and chronic obstructive pulmonary disease were included in the new list, which will further improve the level of protection. In the last edition of the national medical insurance drug list, the NSN sodium injection, which was once used for the treatment of spinal muscular atrophy at 70000 yuan per injection, was included in the medical insurance at more than 30000 yuan after the medical insurance negotiation. As a competitive product of Nosenacin sodium injection, Lispiran, also suitable for the treatment of spinal muscular atrophy, has successfully entered the new version of the medical insurance drug list. The drug is used according to age and weight, which will bring higher cost performance for young and small children. It is reported that the vast majority of new drugs in this catalog are new drugs launched within five years; Of the 111 new drugs, 23 were approved in 2022, and were immediately included in the current year's list; The negotiation of 20 major domestic innovative drugs was successful, with a success rate of 83.3%, higher than the overall negotiation success rate. In the field of anti-tumor, this negotiation not only added new drugs with significant curative effects such as loratinib, but also significantly decreased the prices of drugs such as ensatinib in the previous catalogue. Take Xindiliximab produced by Xinda Bio-pharmaceutical Group as an example. This drug covers the high incidence of lung, stomach, esophagus and other tumor types. The cost of medical insurance reimbursement has been greatly reduced, which benefits more patients. The average price reduction of 60% of the medical insurance negotiation does not blindly pursue the "floor price". The price reduction of the new negotiated competitive drugs has reached 60.1%, which is basically the same as that of last year. The double negative effects of negotiated price reduction and medical insurance reimbursement are superimposed. "Huang Xinyu said that in the next two years, the new version of the medical insurance drug catalog is expected to reduce the burden of patients by more than 90 billion yuan. As a hematopoietic stem cell malignant disease mainly characterized by myeloid hyperplasia, there are about 1000 new patients with chronic myeloid leukemia with T315I mutation in China every year, and they face the problem of no medicine to cure for a long time. After more than one hour of on-site negotiation, the negotiation of Orebatini of Yasheng Pharmaceutical was successful. It is the first domestic innovative drug used to treat chronic myeloid leukemia with T315I mutation in China, filling the gap in the list of medically insured drugs. Compared with the previous retail price, the annual treatment cost is nearly 50% lower